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Objective: Evaluate depression scores, response, and remission rates in patients with major depression receiving
adjunct therapy with folate (L-Methylfolate or folic acid) compared to selective serotonin reuptake inhibitor or
serotonin-norepinephrine reuptake inhibitor (SSRI or SNRI) monotherapy.
Methods: Academic Search Premier, CINAHL Complete, Cochrane Database of Systematic Reviews, Medline with
Full Text, PsychInfo, PubMed, ClinicalTrials.org, and Google Scholar were searched utilizing specific key words.
Identified studies were independently screened for inclusion by two reviewers, were assessed for risk of bias
using the Revised Cochrane risk-of-bias tool (RoB2), then meta-analyzed using a random effects model with
Review Manager (5.4) software.
Results: The initial search revealed 293 articles with 6 randomized control trials ultimately meeting inclusion
criteria. In patients with depression, analysis of 5 studies revealed a significantly lower Hamilton Depression
Rating Scale (HAM-D) score in individuals treated with adjunct therapy with L-Methylfolate/folic acid [Mean
Difference (MD): -2.16 (95 % CI -3.62 to -0.69), p = 0.004], as well a combined HAM-D and Beck Depression
Inventory-II (BDI-II) scores [standardized mean difference (SMD): -0.61 (95 % Confidence Interval {CI} -0.97 to
-0.24), p = 0.002]. This adjunct therapy also yielded an improved response rate [Risk Ratio (RR): 1.36 (95 % CI:
1.16–1.59) P = 0.0001], increase in remission rate [RR: 1.39 (95 % CI: 1.00–1.92) P = 0.05], and reduction in
depression scores after varying durations of treatment, 4 week: [SMD = -0.38 (95 % CI: –0.55 to -0.22) P ≤
0.00001]; 6 week: [SMD = –0.94 (95 % CI: –1.85 to -0.03) P = 0.04]; ≥ 8 week: [SMD= -0.57 (95 % CI: -0.91 to
-0.23) P = 0.0009].
Conclusion: Adjunct therapy with L-Methylfolate or folic acid improves depression scale scores, patient response,
and remission rates.

1. Introduction
Major Depressive Disorder (MDD) is one of the most common mental
disorders in the United States with an estimate of 11 million individuals
over the age of 18 experiencing a MDD episode a year.1 It is predicted
that over the next 13 years, depression will be the leading cause of
disability in the United States.2,3 The Diagnostic and Statistical Manual
of Mental Disorders characterizes MDD as a change in mood, anhedonia,
lack of interest, little to no energy, change in appetite, change in weight,
and feelings of worthlessness for a majority of days in a 2-week period.

Individuals with MDD have a diminished quality of life, and experience
functional impairment compared to their baseline characteristics. If left
untreated, depression will lead to increases in both morbidity and
mortality.
The primary objective of MDD treatment is for a patient to achieve an
almost complete remission of depression with restoration of function.4
In order to assess the efficacy of treatment, patient response followed by
remission is evaluated. Response is considered ≥ 50 % reduction in total
symptoms experienced by patients upon receiving treatment. The ulti
mate goal of depression treatment is to achieve remission. Remission is

Abbreviations: BDI-II, Beck Depression Inventory-II; CI, confidence interval; HAM-D, hamilton depression scale; MD, mean difference; MDD, major depression
disorder; RoB, risk of bias; RR, risk ratio; SMD, standardized mean difference; SNRI, serotonin norepinephrine reuptake inhibitors; SSRI, Selective serotonin reuptake
inhibitors.
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birth, and colorectal cancer.19–22 There have also been several
meta-analyses and systematic reviews examining the role of folate in
mood disorders. Hsieh et al. examined serum folate levels in patients
with bipolar disorder concluding that there was a presence of low serum
levels in patients within the study.26 Another meta-analysis conducted
in 2017 specifically assessed serum levels in patients with depression
also stating low levels of serum folate in depressed individuals.18 Last,
Firth et al. identified that the addition of various vitamin B substances to
schizophrenia treatment was associated with a reduction in psychiatric
symptoms.27 In contrast other studies, such as Christensen et al., re
ported that there was no benefit in the addition of a combination of both
folic acid and vitamin B12 to antidepressant medication.28 This con
flicting data suggests that there is further investigation needed between
folic acid and MDD. Given the relatively frequent failure of antide
pressants and low symptom remission rate using first line treatment of
SSRI/SNRI, there is a need for additional methods to be used as adjunct
in the treatment of depression. Moreover, these treatment challenges
have been magnified in the past year by the COVID-19 pandemic. Not
only does evidence suggest that the social isolation imposed by
mandatory lockdowns exacerbated overall mental health, but it also
appears that the virus itself may further worsen the mental wellbeing of
those who are infected.29,30
Folate is considered to be water soluble B vitamin; it is considered to
be safe as it has very limited drug interactions and few side effects.
Moreover, it is inexpensive and thus can be considered low risk as an
adjunctive therapy.31 For the purposes of this review, vitamin B-9 sup
plementation will be specifically referring to L-Methylfolate (Levome
folic acid) and folic acid. Currently, there is no literature review or
meta-analysis that focuses on the adjunct treatment role of vitamin
B-9 in combination with a SSRI or SNRI for treatment of depression. The
primary objective of this review is to evaluate the impact on depression
scale scores, response rates, and overall remission when SSRI/SNRI are
supplemented with vitamin B-9.

defined as a reduction in one of the six categories: return of baseline
functioning at work, home, or school, functional autonomy, positive
relationships with others, emotional control, positive personal growth,
and no depressive symptoms.5 Current guideline recommended treat
ment for MDD consists of monotherapy with an antidepressant such as:
selective serotonin reuptake inhibitors (SSRIs), serotonin norepineph
rine reuptake inhibitors (SNRIs), mirtazapine, or bupropion.2,6,7 These
classes of medications work by blocking the reuptake of monoamine
transmitters in the synapse leading to an increase in transmitters.
Although SSRI/SNRI monotherapy has been utilized for years, it may
take 3–6 weeks for patients to respond to treatment and many have little
to no improvement in function. Additionally, side effects of antide
pressants can be distressing for patients and as a result lead to dis
continued antidepressant use, and withdrawal.8–13 Moreover, while
these medications remain the gold standard of initial treatment, the
overall efficacy is modest as evidenced by studies such as the Sequenced
Treatment Alternatives to Relieve Depression (STAR*D) study which
showed that antidepressants achieved only a 30 % remission rates in
individuals, and more than 70 % of patients were not able to maintain
remission.12,14,15 With more than 60 % of patients treated with standard
SSRI/SNRI monotherapy unresponsive to treatment, clinicians are left
with the challenge of what to consider next.16 When monotherapy fails,
alternatives include increasing the dosage, switching to a different an
tidepressant, or augmenting with a psychotropic or antipsychotic
medication. These additions or alterations may incur several undesir
able side effects and can still be unsuccessful in improving patient
symptoms. Therefore, it becomes imperative to provide safer and effi
cacious alternatives to treatment resistant depression.
A novel approach to a safe and efficacious alternative for patients
with an inadequate response to standard antidepressant is augmentation
with pharmaceutical grade nutrients, known as nutraceuticals, such as:
L-Methylfolate, S-Adenosyl Methionine, Vitamin E, and Omega 3 Fatty
acid. Specifically, folic acid or it’s metabolically active form, L-Methyl
folate, is of promising due to its correlation with increased risk of
depression, severe depressive symptoms, prolonged duration of
depressive episodes, and increased risk of relapse.17–21 Furthermore,
depressed patients with folate deficiency demonstrated limited to no
response upon receiving antidepressant treatment.20,22 Therefore, folate
augmentation with standard antidepressant medication may improve
treatment outcome in patients with low folate levels.22,23 A retrospec
tive analyses comparing patients with SSRI or SNRI monotherapy versus
those treated with a combination of an SSRI/SNRI antidepressant and
L-Methylfolate (7.5 mg or 15 mg) found adjunct therapy with L-Meth
ylfolate in patients with MDD was more efficient, led to symptom
improvement, and had fewer patients discontinue medications.14,22
Evidence suggests this correlation between folic acid and depression
symptoms; however, while not fully understood, the monoamine hy
pothesis may explain its role. Folic acid plays an essential role in onecarbon metabolism and has been linked with the synthesis of mono
amines such as serotonin, epinephrine, and norepinephrine.24 Folic acid
is considered to be an essential nutrient, meaning that it is required for
normal body functioning; however, it is not synthesized in the body, but
obtained through the consumption of food. Once in the body, folic acid
is converted into L-Methylfolate by the enzyme methylene tetrahy
drofolate reductase, also known as MTHFR. After its conversion to
L-Methylfolate it crosses the blood brain barrier. L-Methylfolate is known
to aid in the formation of BH4, or tetrahydrobiopterin, which activates
tyrosine hydroxylase and tryptophan hydroxylase which aid in the
synthesis of monoamines.8,24 A study showed that patients with psy
chiatric illnesses such as schizophrenia, bipolar disorder, autism and
major depression are found to have a MTHFR gene mutation.25 MTHFR
gene mutation results in low levels of L-Methylfolate in the CNS, leading
to a depletion of monoamines alluding to the benefit patients may
experience with supplementation.24
There have been many medical conditions that appear to be
impacted by folate, such as cardiovascular disease, strokes, preterm

2. Methods
2.1. Search strategy
An initial, comprehensive search was conducted on March 20, 2020.
Six databases were searched including PubMed. The EBSCO Information
Services was used to search the following databases: Academic Search
Premier, CINAHL Complete, Cochrane Database of Systematic Reviews,
Medline with Full Text, and APA PsychInfo. Furthermore, grey literature
was searched using ClinicalTrials.org and Google Scholar. The Boolean/
phrases search strategy was utilized with the following terms, (“major
depressive disorder” or “depression” or “depressive disorder”), AND
(“folate” or “methylfolate”). In order to conduct a targeted search, the
following SSRI/SNRI medications were added to the search strategy:
Fluoxetine OR Prozac, Sertraline OR Zoloft, Paroxetine OR Paxil, Esci
talopram OR Lexapro, Fluvoxamine OR Luvox, Citalopram OR Celexa,
Desvenlafaxine OR Pristiq, Duloxetine OR Cymbalta, Levomilnacipran
OR Fetzima, Milnacipran OR Savella, and Venlafaxine OR Effexor. No
limits were placed on publication date. Limits included peer-reviewed
articles and in the English language. The search strategy was conduct
ed with the assistance of the Sacred Heart University Health Sciences
Librarian and was completed on March 25, 2020. A supplemental tar
geted search was conducted July 2, 2021 to identify if any additional
articles were published during the peer-review process.
2.2. Study selection and eligibility criteria
Publication selection followed the PICOS acronym: Patient/Popu
lation: adult patients with major mental disorders (schizophrenia, bi
polar disorder, and MDD) based on any diagnostic criteria. Intervention:
folic acid (including methylfolate that is a body’s most active form of
folate) combined with treatment as usual (TAU). Control: TAU or TAU
2
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plus placebo. Outcomes: primary outcome was symptomatic improve
ment measured by any standardized rating scales, such as the Hamilton
Depression Rating Scale (HAMD) or the Beck Depression Inventory (BDI)
for depression, the Positive and Negative Syndrome Scale (PANSS) or
The Brief Psychiatric Rating Scale (BPRS) for psychotic symptoms, and
the Young Mania Rating Scaling (YMRS) for mania. Key secondary
outcome measures in efficacy and safety: response and remission rate
defined by individual study; all cause discontinuation; and incidence of
various side effects. Study: RCTs.
Prior to screening titles and abstracts, inclusion and exclusion
criteria were developed. The following inclusion criteria we applied:
patients over 18 years old, patients that met criteria for depression/
major depressive disorder (MDD) using a screening tool, and treatment
with an SSRI/SNRI for depression/MDD. Exclusion criteria included:
patients under 18 years old, patients previously on L-Methylfolate or
folic acid, patients experiencing psychotic or manic features, patients
with untreated hypothyroidism, patients with a risk of suicide or ho
micide, patients with substance use disorder, patients currently being
treated with an antidepressant other than SSRI/SNRI for depression/
MDD, and women who are pregnant or breastfeeding.

into Covidence, 164 duplicates were removed leaving 131 titles and
abstracts to screen for relevance. After screening, 11 articles underwent
full text review to apply inclusion/exclusion criteria, with 6 studies
subsequently excluded. A total of 5 articles containing data from 6
randomized control trials were included for analysis of adjunct vitamin
B-9 therapy in patients with MDD. The 6 randomized control trials
included a total number of 584 patients for quantitative meta-analysis
(see PRISMA flow diagram in Fig. 1).
3.2. Risk of bias
Version 2 of the Cochrane risk of bias tool for randomized trials (RoB
2.0) was used to assess the included studies. Each study was determined
to have a risk of bias considered as either low or some concerns using the
five RoB 2.0 domains (See Table 1).
3.3. Study characteristics
Two studies provided results for patients at the beginning, during,
and end of treatment.33,34 Single site centers were utilized in three of the
studies,35–37 while multicenter sites were utilized in the other two.33,37
Five studies defined outcome measures for responsiveness as a 50 %
reduction score from baseline.,33–3537Three studies defined outcome
measures for remission rate ≤ 9 on the HAM-D scale.33,37 Additional
study characteristics are displayed in Appendix A1.

2.3. Data extraction and risk of bias assessment
Results from the search were exported into Covidence (Covidence.
org) to facilitate screening, selection, and data abstraction. After du
plicates were removed, titles and abstracts were screened and followed
by a full-text review. Risk of Bias was assessed using the Revised
Cochrane risk-of-bias tool for randomized trials (RoB 2). Randomization
process, deviations from intended interventions, missing outcome data,
measurement of outcome, and selection of the reported results were
assessed to determine the overall risk of bias for each study. The overall
risk of bias for each study was classified as low, high, or some concerns.
All steps were independently conducted by two reviewers (RA and IG),
and disputes were resolved by discussion.

3.4. Results efficacy of vitamin B-9
3.4.1. Response and remission
While the primary outcome of the included studies was a depression
scale score, a more clinically meaningful evaluation includes the impact
of supplementation on treatment response and remission as indicator of
efficacy for major depressive disorder. Response was defined as ≥ 50 %
reduction in depression score from baseline in five studies 33–35,37
Remission rate was defined as a HAM-D score of ≤ 9 and was reported in
three of the studies.33,37
A total of 566 patients were evaluable for impact on MDD response
rate (adjunct therapy n = 279; monotherapy n = 287). There was a
clinically significant improvement in response rate that favored patients
receiving adjunct vitamin B-9 compared to patients receiving mono
therapy SSRI/SNRI [RR: 1.36 (95 % CI: 1.16–1.59) P = 0.0001; See
Table 2].
An analysis of reported remission rates in 216 patients (adjunct
therapy n = 104; monotherapy n = 112) also yielded an improvement in
the supplement group [RR: 1.39 (95 % CI: 1.00 to 1.92) P = 0.05; See
Table 3]; however, this was based on an analysis of only three trials.

2.4. Statistical analysis
Review Manager (RevMan) 5.4 software was utilized to conduct a
meta-analysis of 6 RCT’s. Data for differences in depression score from
baseline to end of treatment for patients receiving adjunct vitamin B-9 in
conjunction with an SSRI/SNRI and monotherapy with an SSRI/SNRI
was extracted manually from each study and imported into RevMan. The
mean difference (MD) and standard mean difference (SMD) for changes
in depression scores was calculated with a 95 % confidence interval (CI)
for continuous variables. The SMD was utilized to combine trials that
reported outcome measures on different depression scales (e.g. HAM-D
and BDI-II). The risk ratio (RR) with 95 % CI were calculated for
dichotomous variables. The random effects model was applied to esti
mate the pooled effect for included studies. Outcome measures of p <
0.05 were considered to be statistically significant. The Chi Square test
and I2 were utilized to evaluate heterogeneity. A Chi Square of p ≤ 0.10
was considered statistically significant. An I2 of 50%–90% was classified
as substantial heterogeneity and 75%–100% was classified as consid
erable heterogeneity according to the Cochrane Collaboration recom
mendations.32 To assess potential sources of heterogeneity subgroup
analyses were conducted with the following subtypes: 4 weeks, 6 weeks,
and ≥ 8 weeks of treatment as well as comparing folic acid to methyl
folate. The data analyzed is represented in the form of forest plots.

3.4.2. Difference in depression scores
HAM-D scores evaluate the severity and frequency of symptoms, and
therapeutic efficacy in clinical trials. Five studies utilized the HAM-D
depression scale score,33–35,37 while Sepehrmanesh et al. utilized the
BDI-II. Therefore, a raw Mean Difference (MD) was calculated to
conduct meta-analysis of the five studies utilizing only the HAM-D scale;
and the Standard Mean Difference (SMD) was calculated when the BDI-II
was included into the overall analyses of all six studies.
The analysis of the five HAM-D studies,33–35,37 yielded a significant
improvement in depression scores from baseline, [MD: -2.16 (95 % CI
-3.62 to -0.69), p = 0.004] in favor of adjunct vitamin B-9. Furthermore,
results from the pooled meta-analysis which included HAM-D and BDI-II
scores demonstrated similar results. The data analysis and overall effect
for the studies are displayed in Tables 4 and 5.
The full benefit of SSRI/SNRI may not be seen for up to 8 weeks.
Thus, to further evaluate the effects of vitamin B-9 a subgroup analysis
was conducted to identify pooled SMD of adjunct treatment at 4, 6, and
≥ 8 weeks, respectively. There was a small but significant improvement
in depression scores at 4 weeks [SMD = -0.38 (95 % CI: –0.55 to -0.22) P

3. Results
3.1. Study selection
The database search yielded 293 articles with two additional studies
identified through grey literature; there were no additional articles
identified in the targeted supplemental search update. After importing
3
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Fig. 1. PRISMA Flow Diagram.
Table 1
Cochrane Risk of Bias.

≤ 0.00001]. This is indicative of an enhanced response time leading to a
rapid improvement of symptoms in patients being supplemented with
vitamin B-9. Furthermore, improvements in depression scores continue
to persist at both 6 weeks and 8 weeks. There is a possible synergistic
effect as provided by evidence in support of vitamin B-9 as an efficacious
adjunct therapy. The meta-analysis for the subgroups is displayed in
Table 6.
Last, while the hypothesis of this review focused on adjunct vitamin
B-9, authors investigated if either the folic acid and methyl folate

preparations were individually responsible for the improved outcomes
and compared as a subgroup analysis (see Table 7). Overall, both
products yielded a significant improvement.
3.4.3. Reporting Bias
A funnel plot was created, and asymmetry was identified; however, it
was not included due to insufficient studies included in the metaanalysis which would likely underpower the test used.36

4
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Table 2
Risk ratio for response rate of vitamin B-9 augmentation.

Table 3
Risk Ratio of remission rate of vitamin B9 augmentation.

Table 4
Forest plot of weighted mean difference in Hamilton Rating Scale for Depression (HAM-D) change.

Table 5
Forest plot of standardized mean difference in depression scores change.

3.4.4. Adverse events
There were four studies that provided data for adverse even
ts.33,36,37These studies reported categories of adverse events which
included: sleep disturbance, psychological, somatic, infectious, cardio
vascular, sexual, and miscellaneous; however, the most common
adverse effects reported were gastrointestinal issues and somatic
symptoms. There appeared to be no increased risk of experiencing these
adverse effects beyond what is typically seen with treatment of either of
SSRI/SNRI or folate alone.38 Moreover, based upon a recent review,
there are no established adverse reactions for folic acid when used at a
normal doses, similar to those in the included literature.39 One study
actually reported there were more adverse effects in the monotherapy
SSRI group compared to patients who were on adjunct therapy with folic
acid suggesting the possibility of vitamin B-9 alleviating side effects
caused by SSRI/SNRI33; however, the remainder of studies found no
significant differences between groups.

4. Discussion
4.1. Summary of findings
The present systematic review and meta-analysis of six randomized
control trials demonstrated that the addition of vitamin B-9 to SSRI/
SNRI therapy has both statistical and clinically significant evidence that
it can decrease symptoms for patients with MDD. Participants who took
vitamin B-9 combined with SSRI/SNRI had a 36 % increase in response
rate compared to those on monotherapy, with a number needed to treat
(NNT) of 5. Furthermore, patients on adjunct therapy with vitamin B-9
had a 39 % increase in achieving remission compared to patients on
SSRI/SNRI alone, with a NNT of 9. Differences in depression scores from
baseline to post treatment among individuals with MDD who receive
supplementation with vitamin B-9 to an SSRI/SNRI were significantly
decreased (MD: 2.16 and SMD: 0.61) versus monotherapy. Subgroup
analyses showed an improvement of depressive symptoms for patients in
5
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Table 6
Forest Plot of Depression Scores at different treatment durations.

Table 7
Forest Plot of Depression Scores based upon Adjunct agent.

the experimental group taking supplementation, indicating its efficacy
early on in treatment (4 weeks) which persists throughout the duration
of treatment (≥ 8 weeks).
It has been reported in the STAR*D study that the use of mono
therapy SSRI/SNRI for MDD has not been consistently effective in
achieving remission and/or response.15 In fact, another study found that
within one year patients diagnosed with MDD would be 8 times more
likely to receive adjunct therapy with second generation antyp
sychotics.40 This meta-analysis suggests that the augmentation of
vitamin B-9 is more effective and safe in reducing depressive symptoms
than monotherapy of SSRI/SNRI alone.

contribute to this significant degree of heterogeneity as indicated by the
high heterogeneity results in week 6. Additionally, the RoB 2.0 for
Resler et al. demonstrated overall some concerns due to the randomi
zation process, missing outcome data from participants, and reports of
the results, again contributing to the overall heterogeneity of the metaanalysis. Another contributing factor to heterogeneity is that the metaanalysis included a relatively small overall sample size of 584 partici
pants. The smallest study included 27 participants,36 and the largest
study included 260 participants.35
Another limitation is the variance within study design characteris
tics. The treatment duration varied with the shortest treatment period of
4 weeks and the longest being 10 weeks of treatment, providing only the
opportunity to evaluate the short-term efficacy of vitamin B-9. This
warrants the need for studies which will evaluate the long-term efficacy
and safety of vitamin B-9. Additionally, varied doses of L-Methylfolate
and folic acid were given to participants, diagnostic criteria differed
between studies, and the depression scales utilized varied between
studies, (See Appendix A). There were also slight variations within the
participant inclusion criteria. Participants were required to have a
minimum score at baseline to be included within the study which may
have led clinical assessors to inflate baseline scores unknowingly. There
is a need for higher quality randomized controlled trials to better
quantify the impact of supplementation on remission rates.

4.2. Review/study limitations
Limitations at the review level were specific to the search strategy
such as missing keyword terms and MeSH search terms that could have
resulted in the retrieval of additional results. Additionally, the number
of database searches could have been broadened. Further review limi
tations were observed at the study level.
Results from the meta-analysis are hindered by substantial hetero
geneity (X2 p = 0.002 and I2 of 73 %). The subgroup analysis on the
duration of treatment for individuals given adjunct vitamin B-9
exhibited mixed levels of heterogeneity. Resler et al. seemed to
6

R. Altaf et al.

Complementary Therapies in Medicine 61 (2021) 102770

5. Conclusion

CRediT authorship contribution statement

This systematic review and meta-analysis provide supporting evi
dence for the addition of vitamin B-9 to SSRI/SNRI to be effective and
safe in the treatment of MDD. Vitamin B-9 supplementation is a safe
treatment that improves response, remission, and overall MDD scale
scores.
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Appendix A1 Baseline Study Characteristics
Author(s) & Year

Study
design &
duration

N

Intervention

Diagnostic
Criteria

Age (Years)

Gender
M/F (n)

Mean Depression
Scores at Baseline

Outcome Measures

Resler, G, et al.
(2008)

RCT
6 Weeks

27

Fluoxetine (20 mg) +
folic acid (10 mg/ per
day)

DSM-IV

21− 58 yrs
35.04
+/-2.63

4/23

Folic acid:
22.50+/-0.39
Placebo: 21.85+/0.94

Kakar, M.S., et al.
(2016)

RCT
4 weeks

260

Escitalopram and LMethylfolate (15 mg/
day)

ICD-10

20− 60 yrs
37.4 +/10.4

58/72

Coppen & Bailey
(2000)

RCT
10 weeks

127

Fluoxetine (20 mg/day)
+ folic acid (500
micrograms/day)

DSM-III-R

>18 yrs
+/- N/A

40/69

L-Methylfolate:
17.88+/- 1.95
Placebo: 18.24+/2.42
Folic acid: 26.8+/5.0
Placebo: 26.6+/4.0

1) Folic acid effects on Serotonin
and 5-Hydroxyindoleacetic
Acid
2) response in HAM-D scores from
baseline.
3) Plasma levels of folate,
homocysteine, and vitamin B12
1) Response in HAM-D score from
baseline

Sepehrmanesh, Z., et
al (2016)

RCT
8 weeks

90

Citalopram (20 mg/
day) +2.5 mg folic acid

DSM-IV

20− 50 yrs
35.73 +/9.57

34/56

Papakostas, G., et al
(2012) 1 st Trial

RCT
4 weeks

68

SSRI + L-Methylfolate
(7.5 mg)

DSM-IV

18− 65 yrs,
47.9+/11.6

Not given

Papakostas, G., et al
(2012) 2nd Trial

RCT
4 Weeks

39

SSRI + L-Methylfolate
(15 mg)

DSM-IV

18− 65 yrs
48.4+/12.1

Not given

Folic acid:
30.11+/-10.41
Placebo: 31.24+/10.26
L-Methylfolate:
16.2+/-3.4
Placebo: 16.8+/4.7
L-Methylfolate:
19.5+/-3.8
Placebo: 17.6+/4.5

1) Response in HRS score from
baseline
2) Plasma Folate levels
3) homocysteine levels
4) Vitamin B 12 levels
1) Response in BDI-II from
baseline
2) Response in Hamilton HAM-A
from baseline
1) difference in response rates on
HAM-D
2) degree of improvement.
3) continuous change in scores on
the QIDS-SR and CGI severity
scale
1) Difference in response rates on
HAM-D
2) degree of improvement.
3) continuous change in scores on
the QIDS-SR and CGI severity
scale

RCT = Randomized Control Trial, HRS=Hamilton Depression Rating Scale, HAM-D= Hamilton Depression Rating Scale, BDI-II = Beck Depression
Inventory Scale-II, QID-SR = Quick Inventory of Depressive Symptomatology–Self-Rated, CGI Severity Scale = Clinical Global Impressions Scale, SSRI:
Selective Serotonin Reuptake Inhibitor, DSM = Diagnostic and Statistical Manual of Mental Disorders, ICD = International Classification of Diseases,
mg = milligrams
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